Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA
Created by News on 4/16/2009 9:27:38 AM

Vion Pharmaceuticals, Inc. (OTC Bulletin Board: VION) today announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin (laromustine) Injection has been accepted for review by the U.S. Food and Drug Administration (FDA).


NEW HAVEN, Conn., April 16 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (OTC Bulletin Board: VION) today announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin (laromustine) Injection has been accepted for review by the U.S. Food and Drug Administration (FDA).

The Company had previously announced the filing of the NDA with the FDA in February 2009. The NDA presents data for Onrigin as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The NDA is based on the results of an international multi-center pivotal Phase II trial of 85 patients sixty years of age or older with de novo poor-risk AML, supplemented by data from 55 patients in a previous Phase II trial in elderly AML. Eighty-six percent of these 140 patients had two or more risk factors that predicted for a poor prognosis.

Alan Kessman , Chief Executive Officer, commented, "Acceptance of our NDA filing for review is an important milestone for Vion. We will continue to work closely with the FDA on the filing with the objective of achieving approval for Onrigin in its first indication in the United States."

About Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin (laromustine) Injection and Triapine(R). The FDA is reviewing a New Drug Application for Onrigin for remission induction treatment for patients sixty years of age or older with de novo poor-risk AML. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin (laromustine) Injection (formerly Cloretazine (VNP40101M)), delays in the regulatory approval process, particularly for Onrigin (laromustine) Injection, including possible rejection by the FDA of our request for priority review, and possible delays in the FDA's review process beyond our expectation for approval in the second half of 2009, delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2008, and "Risk Factors" in Vion's Post-Effective Amendments on Form S-1 Registration Statement filed on March 23, 2009. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT:     Vion Pharmaceuticals, Inc.
Alan Kessman, Chief Executive Officer
Howard B. Johnson, President & CFO
(203) 498-4210

 

print
The comment feature is locked by administrator.
Search News
Top Stories

Apr24 Dental Health Products, Inc. (DHPI) Announces Strategic Alliance with the Dental Exchange
Created by Admin on 4/24/2015 9:24:38 AM

 Dental Health Products, Inc. (DHPI) and The Dental Exchange have announced the formation of a ne...
Read More..

Mar12 Dr. Richard Hughes Named an Honored Fellow of the American Academy of Implant Dentistry
Created by udent webmaster on 3/12/2015 11:04:13 AM

The American Academy of Implant Dentistry (AAID) has named Dr. Richard Hughes an Honored Fellow due ...
Read More..

Mar12 Deerfield Delivers Superior Veterinary Dentistry with Elite Drill
Created by udent webmaster on 3/12/2015 10:41:57 AM

One of Springfield’s leading animal hospitals continues its commitment to providing the best in vete...
Read More..

Mar12 Studio B Dental Launches New Website Specifically for Their All on 4 Dental Implant Procedure
Created by udent webmaster on 3/12/2015 10:39:47 AM

The new website launched by the popular Toronto dental clinic offers a simple 2 minute assessment fo...
Read More..

Mar09 Dr. E. Dale Behner Gives Indianapolis, IN Residents Access to a Minimally Invasive Receding Gums Treatment
Created by udent webmaster on 3/9/2015 10:09:50 PM

Dr. E. Dale Behner of Dental Care Today, PC is expanding his practice to offer help to those with re...
Read More..

Mar09 Growing Emphasis on Prevention of Caries Drives the Global Dental Preventive Supplies Market, According to a New Report by Global Industry Analysts, Inc
Created by udent webmaster on 3/9/2015 10:06:00 PM

Dental caries or tooth decay is one of the major issues for public healthcare systems in most countr...
Read More..

Mar07 Dr. John Schiro DDS Opens New Cosmetic Dentistry Practice in Austin, Texas
Created by udent webmaster on 3/7/2015 4:10:59 PM

Dr. John Schiro DDS is now announcing the grand opening of his new cosmetic dentistry practice in A...
Read More..

Mar20 One Third of Americans Still in Need of Affordable Dental Care Options
Created by Melissa Watkins on 3/20/2014 11:46:00 AM

According to Healthcare.gov, the Health and Human Services arm that is in charge of the federal heal...
Read More..

Feb11 DENTALPLANS.COM CREATES ONLINE PROJECT CENTER FOR NATIONAL CHILDREN’S DENTAL HEALTH MONTH
Created by Melissa Watkins on 2/11/2014 12:50:00 PM

 etting children to brush and floss every day isn’t always easy, especially when parents have a mil...
Read More..

Feb10 126.7 MILLION AMERICANS IN NEED OF DENTAL CARE OPTIONS
Created by Melissa Watkins on 2/10/2014 11:13:00 AM

 As the Affordable Care Act (ACA) discussion switches from accessing the federal and state health e...
Read More..

Jan21 DENTALPLANS.COM APPOINTS BOB HARRIS CHIEF EXECUTIVE OFFICER
Created by Melissa Watkins on 1/21/2014 3:39:00 PM

 entalPlans.com, a leading provider of dental savings plans, has named Bob Harris as chief executiv...
Read More..

Oct16 Keep Your Teeth White !
Created by Mint Cosmetics Review on 10/16/2013 11:58:00 PM

Great plastic is a teeth bleaching package which is prescribed by simply the majority of the dental ...
Read More..

Aug01 Gummy Smiles: What Are My Treatment Options?
Created by mapleavenuefamilydentistry on 8/1/2013 6:29:00 AM

When most people smile, you see a row of teeth that look beautiful and full. Unfortunately, this is ...
Read More..

Jul27 Plastic Surgeons Nj – A Smart Gateway To Beautification
Created by Dr. Michael A. Fiorillo, MD on 7/27/2013 12:05:00 AM

Plastic Surgeons Nj are veterans in the field of plastic surgery. These surgeons can completely cha...
Read More..

Jul22 Dental Implants: Evidence of Modern Dentistry
Created by paul589649 on 7/22/2013 4:50:00 AM

You can find out more about -   Dentist West Hartford CT , Dental Implants West Haven CT , De...
Read More..

Oct22 Guidance of Taking Good Care Of Braces
Created by bonniemendes on 10/22/2012 11:50:00 PM

 Guidance of Taking Good Care Of Braces Finding dependable techniques for taking care of braces as ...
Read More..

Aug13 Periodontist Comments On New Study Examining Diabetes Drug That May Be Able To Fight Oral Cancer
Created by Dr. Alex Farnoosh on 8/13/2012 12:24:00 PM

About The Total Smile: The Total Smile was founded by Beverly Hills Periodontist Dr. Alex Farn...
Read More..

Jul17 360imaging releases an improved version 4 of 360DPS dental implant planning software
Created by Manal on 7/17/2012 4:25:00 AM

 360 Imaging – an industry leader in dental implant planning - recently announced the release of  v...
Read More..

Jul11 iCare Financial Launches Strategic Alliance With Concorde Communications To Benefit Growth Of Dental Practices
Created by iCare Credit on 7/11/2012 4:28:00 PM

iCare Financial, a leading provider of patient credit, and Concorde Communications, an acclaimed me...
Read More..

Jun26 Periodontist Discusses Study Linking Osteoporosis Drug Complications To Patients With Certain Genes
Created by Dr. Alex Farnoosh on 6/26/2012 10:14:00 AM

On the heels of an earlier study linking antiresorptive drugs to medication induced osteonecrosis...
Read More..